PLA1A and Duchenne muscular dystrophy: In diseases like cystic fibrosis, Duchenne muscular dystrophy (DMD), and spinal muscular atrophy, therapies that combine NMD inhibition with read-through agents or CRISPR-based editing have restored functional protein expression [30,121,122].